302 related articles for article (PubMed ID: 18925528)
21. Challenging the validity of the EPO index.
Kaysen GA; Müller HG; Ding J; Chertow GM
Am J Kidney Dis; 2006 Jan; 47(1):166. PubMed ID: 16377397
[TBL] [Abstract][Full Text] [Related]
22. Optimizing erythropoietin therapy in hemodialysis patients.
Richardson D; Bartlett C; Will EJ
Am J Kidney Dis; 2001 Jul; 38(1):109-17. PubMed ID: 11431190
[TBL] [Abstract][Full Text] [Related]
23. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
24. Oral vitamin C supplementation reduces erythropoietin requirement in hemodialysis patients with functional iron deficiency.
Sultana T; DeVita MV; Michelis MF
Int Urol Nephrol; 2016 Sep; 48(9):1519-24. PubMed ID: 27170339
[TBL] [Abstract][Full Text] [Related]
25. Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients.
Tarng DC; Hung SC; Huang TP
J Am Soc Nephrol; 2004 Sep; 15(9):2486-93. PubMed ID: 15339999
[TBL] [Abstract][Full Text] [Related]
26. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
27. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
28. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism.
Trunzo JA; McHenry CR; Schulak JA; Wilhelm SM
Surgery; 2008 Dec; 144(6):915-8; discussion 919. PubMed ID: 19040997
[TBL] [Abstract][Full Text] [Related]
29. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
[TBL] [Abstract][Full Text] [Related]
30. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
[TBL] [Abstract][Full Text] [Related]
31. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
32. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
33. Minor impairment of oral iron absorption in non-diabetic new dialysis patients.
Tovbin D; Schnaider A; Vorobiov M; Rogachev B; Basok A; Shull P; Novack V; Friger M; Avramov D; Zlotnik M
J Nephrol; 2005; 18(2):174-80. PubMed ID: 15931645
[TBL] [Abstract][Full Text] [Related]
34. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
Lin CL; Hsu PY; Yang HY; Huang CC
Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
[TBL] [Abstract][Full Text] [Related]
35. [Is the management of anemia in hemodialysis patients improving in France? Results of the DiaNE study].
Kessler M; Landais P; Canivet E; Yver L; Bataille P; Brillet G; Commenges B; Koné S
Nephrol Ther; 2009 Apr; 5(2):114-21. PubMed ID: 19042175
[TBL] [Abstract][Full Text] [Related]
36. Septicemia in patients with ESRD is associated with decreased hematocrit and increased use of erythropoietin.
Nissenson AR; Dylan ML; Griffiths RI; Yu HT; Dubois RW
Clin J Am Soc Nephrol; 2006 May; 1(3):505-10. PubMed ID: 17699252
[TBL] [Abstract][Full Text] [Related]
37. Effect rHuEpo on predialysis CRF patients: study of 45 cases.
Islam S; Rahman H; Rashid HU
Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):83-7. PubMed ID: 16967814
[TBL] [Abstract][Full Text] [Related]
38. [Is it necessary to supplement with folic acid patients in chronic dialysis treated with erythropoietin?].
Duclos J; Sieberth HG; Mann H
Rev Med Chil; 1993 Jan; 121(1):30-5. PubMed ID: 8235161
[TBL] [Abstract][Full Text] [Related]
39. Factor deficiency in the anemia of renal transplant patients with grade III-IV chronic kidney disease: baseline results of the ARES Study.
Gentil MA; Pérez-Valdivia MA; López-Mendoza M; Ortega F; Arias M; Gómez-Alamillo C; Campistol JM;
Transplant Proc; 2008 Nov; 40(9):2922-4. PubMed ID: 19010148
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of erythropoiesis on supervised intradialytic oral iron and vitamin C therapy is correlated with Kt/V and patient weight.
Tovbin D; Markowitz A; Mostoslavsky M; Landver R
Clin Nephrol; 2000 Apr; 53(4):276-82. PubMed ID: 10809415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
